Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (PRODIG)
Prevention of New Onset Diabetes After Transplantation by a Short Term Treatment of Vildagliptin in the Early Post-transplant Period
Sponsor: Amiens University Hospital
A PHASE3 clinical study on Diabetes and Disorder Related to Renal Transplantation, this trial is ongoing. The trial is conducted by Amiens University Hospital and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE3
-
Mar 2021 — Sep 2022 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Feb 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amiens University Hospital
- Centre Hospitalier Universitaire de Besancon
- Centre Hospitalier Universitaire de Nice
- Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
- Rennes University Hospital
- Tenon Hospital, Paris
- University Hospital, Brest
- University Hospital, Lille
- University Hospital, Strasbourg, France
- University Hospital, Tours
For direct contact, visit the study record on ClinicalTrials.gov .